Kronos Bio Starts Dosing In Early-Stage Leukemia Study With Next-Gen SYK Inhibitor

The first patient was dosed in Kronos Bio Inc's KRON Phase 1b/2 trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia (AML).
Lanraplenib is the company's next-generation spleen tyrosine kinase (SYK) inhibitor.
The Phase 1b/2 lanraplenib trial is being conducted in two stages: a dose-escalation stage and an expansion stage.
The first stage is evaluating the initial safety, pharmacokinetic and anti-leukemic activity of escalating once-daily doses of lanraplenib in combination with the standard approved dose of gilteritinib.
This stage also will assess FLT3 measurable residual disease (MRD) negative rate in patients who achieve a complete response (CR) and explore the predictive value of several biomarkers that may correlate with clinical outcomes.
An expansion stage is planned to evaluate the safety of lanraplenib further and assess its anti-leukemic activity as measured by CR rate and duration of response.
Price Action: KRON shares are down 4.69% at $4.06 on the last check Monday.